Barinthus Biotherapeutics/$BRNS
1D1W1MYTD1Y5YMAX
About Barinthus Biotherapeutics
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
- Ticker
- $BRNS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 14
- Headquarters
- Germantown, United States
- Website
- www.barinthusbio.com
BRNS Metrics
BasicAdvanced
$30M
-
-$1.02
-0.39
-
Price and volume
Market cap
$30M
Beta
-0.39
52-week high
$1.83
52-week low
$0.51
Average daily volume
36K
Financial strength
Current ratio
5.539
Quick ratio
5.333
Long term debt to equity
15.002
Total debt to equity
18.019
Interest coverage (TTM)
-606.23%
Profitability
EBITDA (TTM)
-31.583
Effective tax rate (TTM)
0.40%
Management effectiveness
Return on assets (TTM)
-18.99%
Return on equity (TTM)
-52.38%
Valuation
Price to book
0.52
Price to tangible book (TTM)
0.68
Price to free cash flow (TTM)
-1.129
Free cash flow yield (TTM)
-88.58%
Free cash flow per share (TTM)
-0.648
Growth
Earnings per share change (TTM)
-40.95%
3-year earnings per share growth (CAGR)
-11.12%
What the Analysts think about BRNS
Analyst ratings (Buy, Hold, Sell) for Barinthus Biotherapeutics stock.
BRNS Financial Performance
Revenues and expenses
BRNS Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.